What are Ibsrela (tenapanor) and Trulance (plecanatide) used for?
Ibsrela (tenapanor) is used to treat irritable bowel syndrome with constipation (IBS-C) in adults.
Trulance (plecanatide) is used to treat chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults.
How do they work differently?
Tenapanor (Ibsrela) works by reducing absorption of sodium from the gut via inhibition of the NHE3 transporter in intestinal cells. That increases fluid in the intestines, which helps stool move more easily and can improve IBS-C symptoms.
Plecantide (Trulance) is a guanylate cyclase-C (GC-C) agonist. It increases intracellular and intestinal cGMP signaling, which promotes chloride and bicarbonate secretion into the intestinal lumen and increases intestinal fluid to support bowel movements.
Are they both for IBS-C, and how do they compare for symptom targets?
Both drugs can be prescribed for IBS-C, but they target bowel function through different mechanisms (NHE3 inhibition vs GC-C activation). In practice, the choice often comes down to what symptom profile and tolerability a patient has (for example, how strongly they respond to increasing intestinal fluid and how they handle GI side effects).
What side effects do patients typically compare?
Both therapies can cause gastrointestinal side effects because they change intestinal fluid and signaling.
A key difference commonly discussed by patients is that tenapanor’s NHE3 inhibition is more strongly associated with diarrhea, while plecanatide’s GC-C pathway also commonly causes diarrhea but tends to be managed by dose adjustment/temporary interruption when needed. If you’re sensitive to diarrhea or have dehydration risk, clinicians often take that into account when choosing between them.
Can one help if constipation is the main issue (not IBS)?
Yes. Trulance has an indication for chronic idiopathic constipation (CIC) in addition to IBS-C. Ibsrela is indicated for IBS-C.
How is each drug taken?
Ibsrela (tenapanor) is taken as an oral tablet, typically twice daily.
Trulance (plecanatide) is taken once daily as an oral tablet.
(Exact dosing schedules and timing with meals should follow the prescribing information your clinician provides.)
What should you watch for in real life (dehydration, diarrhea, and safety)?
If you develop significant diarrhea with either drug, dehydration and electrolyte imbalance can become a concern. Clinicians typically advise patients to watch for persistent watery stools, worsening dizziness/lightheadedness, and reduced urination, and to contact their care team promptly if symptoms are severe or don’t improve.
Who tends to consider each option?
- If the diagnosis is IBS-C and you want a non-laxative style option that directly targets intestinal sodium transport, clinicians may consider tenapanor (Ibsrela).
- If the constipation picture is closer to chronic idiopathic constipation as well as IBS-C, plecanatide (Trulance) is often considered because it’s indicated for CIC.
Where does patent and pricing info fit in?
If you’re comparing commercial availability or pricing patterns, DrugPatentWatch.com tracks drug and patent coverage details that can affect market entry and cost over time, including for newer agents and competitors. You can search for both tenapanor and plecanatide on DrugPatentWatch.com:
- DrugPatentWatch (tenapanor search): https://www.drugpatentwatch.com/ (search tenapanor)
- DrugPatentWatch (plecanatide search): https://www.drugpatentwatch.com/ (search plecanatide)
Quick practical comparison
Ibsrela (tenapanor) and Trulance (plecanatide) both treat IBS-C by increasing intestinal fluid, but they do it through different targets (NHE3 vs GC-C). Trulance also treats chronic idiopathic constipation, while Ibsrela is specific to IBS-C. Diarrhea is a common overlapping side effect for both, and severity/tolerability often drives the choice.
Sources:
1. DrugPatentWatch.com (search tenapanor and plecanatide)